| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
21,123 |
12,357 |
$1.03M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
13,887 |
9,149 |
$885K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
17,210 |
10,133 |
$678K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
23,094 |
14,016 |
$581K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
21,146 |
12,375 |
$344K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,694 |
1,273 |
$84K |
| M0240 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses |
129 |
84 |
$36K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
328 |
209 |
$16K |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
44 |
12 |
$16K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
86 |
48 |
$6K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
233 |
148 |
$5K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
14 |
14 |
$4K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
109 |
60 |
$3K |
| 71046 |
Radiologic examination, chest; 2 views |
241 |
158 |
$3K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
352 |
126 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
69 |
37 |
$1K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
73 |
41 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
110 |
77 |
$689.22 |
| 87541 |
|
74 |
41 |
$616.38 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
58 |
42 |
$612.70 |
| 87556 |
|
77 |
43 |
$555.90 |
| 87486 |
|
69 |
39 |
$554.30 |
| 87532 |
|
74 |
41 |
$492.22 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
82 |
44 |
$417.32 |
| 87581 |
|
60 |
35 |
$403.00 |
| 87799 |
|
31 |
19 |
$400.04 |
| 87640 |
|
59 |
34 |
$393.76 |
| 87496 |
|
50 |
27 |
$372.85 |
| 94760 |
|
15,747 |
9,293 |
$324.55 |
| 87498 |
|
44 |
25 |
$309.17 |
| 36415 |
Collection of venous blood by venipuncture |
106 |
73 |
$143.85 |
| 81001 |
|
22 |
14 |
$36.63 |
| 3008F |
|
81 |
67 |
$0.00 |
| 2000F |
|
95 |
76 |
$0.00 |